1	Molecular analysis for ovarian cancer detection in patient-friendly samples
2	Birgit M.M. Wever ^{1,2} , Mirte Schaafsma ^{1,2,3} , Maaike C.G. Bleeker ^{1,2} , Yara van den
3	Burgt ^{1,2} , Rianne van den Helder ^{1,2,3} , Christianne A.R. Lok ³ , Frederike Dijk ^{2,4} , Ymke van
4	der Pol ^{1,2} , Florent Mouliere ^{1,2} , Norbert Moldovan ^{1,2} , Nienke E. van Trommel ³ , Renske
5	D.M. Steenbergen ^{1,2*}
6	¹ Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Pathology,
7	Amsterdam, The Netherlands
8	² Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands
9	³ Antoni van Leeuwenhoek/Netherlands Cancer Institute, Department of Gynecologic
10	Oncology, Center of Gynecologic Oncology Amsterdam, Amsterdam, The Netherlands
11	⁴ Amsterdam UMC, location University of Amsterdam, Department of Pathology, The
12	Netherlands
13	
14	*Corresponding author: Amsterdam UMC, Vrije Universiteit Amsterdam, Department
15	of Pathology, Cancer Center Amsterdam, De Boelelaan 1117, PO Box 7057, 1007 MB,

- 16 Amsterdam, The Netherlands.
- 17 Telephone: 00-31-204442331; E-mail: r.steenbergen@amsterdamumc.nl

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

18 HIGHLIGHTS

Ovarian cancer is often diagnosed at an advanced stage with a poor prognosis 19 • We studied the potential of molecular testing in different types of patient-friendly 20 • material for ovarian cancer detection 21 Elevated methylation of ovarian cancer-associated genes can be measured in 22 • cervical scrapes and urine 23 Copy number aberrations are detectable in urine of ovarian cancer patients 24 • 25 DNA-based testing in cervical scrapes and urine could aid ovarian cancer • diagnosis upon further development 26

GRAPHICAL ABSTRACT 27



28

29 Created with BioRender.com.

30 ABSTRACT

31 Background

High ovarian cancer mortality rates motivate the development of effective and patientfriendly diagnostics. Here, we explored the potential of molecular testing in patientfriendly samples for ovarian cancer detection.

35 **Patients and methods**

Home-collected urine, cervicovaginal self-samples, and clinician-taken cervical scrapes were prospectively collected from 54 patients diagnosed with a highly suspicious ovarian mass (benign n=25, malignant n=29). All samples were tested for nine methylation markers, using quantitative methylation-specific PCRs that were verified on ovarian tissue samples, and compared to unpaired patient-friendly samples of 110 healthy controls. Copy number analysis was performed on a subset of urine samples of ovarian cancer patients by shallow whole-genome sequencing.

43 Results

Three methylation markers were significantly elevated in full void urine of ovarian 44 cancer patients as compared to healthy controls (C2CD4D, p=0.008; CDO1, p=0.022; 45 MAL, p=0.008), of which two were also discriminatory in cervical scrapes (C2CD4D, 46 p=0.001; CDO1, p=0.004). When comparing benign and malignant ovarian masses, 47 GHSR showed significantly elevated methylation levels in the urine sediment of 48 ovarian cancer patients (p=0.024). Other methylation markers demonstrated 49 comparably high methylation levels in benign and malignant ovarian masses. 50 Cervicovaginal self-samples showed no elevated methylation levels in patients with 51

ovarian masses as compared to healthy controls. Copy number changes were
 identified in 4 out of 23 urine samples of ovarian cancer patients.

54 **Conclusion**

55 Our study revealed increased methylation levels of ovarian cancer-associated genes 56 and copy number aberrations in the urine of ovarian cancer patients. Our findings 57 support continued research into urine biomarkers for ovarian cancer detection and 58 highlight the importance of including benign ovarian masses in future studies to 59 develop a clinically useful test.

60 Keywords

61 Cervical scrape; Copy number aberrations; DNA Methylation; Ovarian cancer; Urine

62 INTRODUCTION

Ovarian cancer is the most lethal gynecological cancer worldwide, accounting for 63 207.252 deaths in 2020.¹ Due to non-specific or absence of symptoms at an early-64 stage, patients typically present at a late-stage when prognosis is poor.² Five-year 65 overall survival rates sharply decrease with higher stage at diagnosis, with 92% 66 survival in early-stage disease compared to only 29% in late-stage disease.³ High 67 mortality rates prioritize the development of novel diagnostic approaches for ovarian 68 69 cancer. Although more ovarian cancer patients were diagnosed at an earlier stage with screening strategies using conventional imaging and/or serum biomarkers (e.g., CA-70 125), this did not translate into reduced overall cancer-specific mortality in general and 71 in high-risk populations.^{4, 5} In fact, the majority of ovarian cancers were not detected 72 during or after the trial. A more accurate and easily accessible test could potentially 73 overcome this problem. 74

Testing for ovarian cancer using biomarkers related to carcinogenesis could offer such 75 an accurate test. DNA methylation-mediated silencing of tumor suppressor genes 76 occurs early in cancer development and is therefore promising to detect cancer at an 77 78 early-stage.⁶ Methylation analysis in urine, cervicovaginal self-samples, and cliniciantaken cervical scrapes has already been proven to allow reliable detection of cervical^{7,} 79 ⁸ and endometrial cancer.^{9, 10} In urine, even signals of non-urogenital cancers, 80 including colorectal¹¹ and lung cancer^{12, 13}, are detectable by methylation testing. The 81 measurement of somatic mutations, aneuploidy, or DNA methylation in clinician-taken 82 cervical scrapes or blood demonstrated the high potential of molecular-based 83 diagnostic tests for ovarian cancer.¹⁴⁻¹⁷ However, these molecular changes have not 84 been investigated in home-collected urine and cervicovaginal self-samples of ovarian 85 cancer patients. 86

In this study, we explored the potential of molecular testing in home-collected urine 87 88 and cervicovaginal self-samples, and clinician-taken cervical scrapes for ovarian cancer detection. Methylation markers considered suitable for the detection of ovarian 89 cancer included a combination of markers described in studies on cervical and 90 endometrial cancer detection in patient-friendly sample types (GALR1, GHSR, MAL, 91 PRDM14, SST, and ZIC1^{10, 18-20}), and ovarian cancer detection in cervical scrapes and 92 plasma (C2CD4D, CDO1, NRN1^{17, 21, 22}). In addition, the analysis of somatic copy 93 number aberrations (SCNA) and fragmentation patterns was performed using shallow 94 whole-genome sequencing on a subset of the samples to verify the presence of ovarian 95 96 cancer-derived DNA in urine.

97

98 MATERIAL AND METHODS

99 Study population

100 This study prospectively included patients with a highly suspicious ovarian mass according to current triage methods (>40% risk of malignancy using the IOTA adnex 101 model).^{23, 24} Paired samples (*i.e.*, urine, cervicovaginal self-samples, and clinician-102 taken cervical scrapes) were consecutively collected within the SOLUTION1 study, 103 between July 2018 and September 2022, at the Antoni van Leeuwenhoek hospital, 104 105 Amsterdam, The Netherlands. Samples were collected from patients who underwent pelvic surgery with post-operatively confirmed ovarian cancer of any stage and 106 histological subtype, and patients with a benign ovarian mass who were referred to a 107 108 highly specialized tertiary oncology unit for further assessment. Patients scheduled for pelvic surgery, involving exploratory laparotomy to determine the origin of their ovarian 109 mass or cytoreductive surgery, were asked to collect samples prior to surgery. Patients 110

without residual tumor/ovarian mass at time of inclusion or no possibility to collect
cytological or urine samples prior to surgery were excluded from participation. Patients
diagnosed with a borderline tumor were also excluded to focus on the most distinct
tumor types in this feasibility stage (*i.e.*, benign and malignant ovarian masses).
Patients of which not all three paired sample types (*i.e.*, cervical scrape, cervicovaginal
self-sample, and urine) were available were not excluded.

117 Control urine samples were obtained from the URIC biobank, including healthy women 118 without any prior cancer diagnosis within the last five years. Control cervicovaginal 119 self-samples and cervical scrapes were collected from high-risk human papillomavirus 120 (hrHPV)-negative women. Both were retrieved from leftover material of the Dutch 121 national cervical cancer screening program coordinated by the Dutch National Institute 122 for Public Health and the Environment (RIVM).

To verify the discriminatory power of the methylation assays and concordance of copy number profiles, formalin-fixed paraffin-embedded (FFPE) and fresh frozen high grade serous ovarian cancer (HGSOC) tissue samples were retrieved from the Pathology archives of Amsterdam UMC, locations AMC and VUmc, Amsterdam, The Netherlands. FFPE normal fallopian tube tissues were collected from patients undergoing a hysterectomy for the treatment of benign endometrial conditions.

129 Sample collection, processing, DNA extraction, and bisulfite modification

The sample collection, processing, DNA extraction, and bisulfite modification procedures were carried out as described previously for cervical^{8, 25} and endometrial cancer.^{10, 19} A detailed description is provided in the Supplemental Methods. Briefly, urine and cervicovaginal self-samples were collected at home and clinician-taken cervical scrapes were collected before surgery. Urine was centrifuged and separated

into two fractions: the urine supernatant and the urine sediment. Both fractions and the
remaining full void urine were stored for further analysis. Following DNA extraction, up
to 250 ng of DNA was subjected to bisulfite modification.

138 DNA methylation analysis by quantitative methylation-specific PCR

Methylation levels of the C2CD4D (gene-ID: 100191040), CDO1 (gene-ID: 1036), 139 GALR1 (gene-ID: 2587), GHSR (gene-ID: 2693), MAL (gene-ID: 4118), NRN1 (gene-140 ID: 51299), PRDM14 (gene-ID: 63978), SST (gene-ID: 6750), and ZIC1 (gene-ID: 141 7545) genes were measured by quantitative methylation-specific polymerase chain 142 143 reactions (qMSP). Methylation markers were multiplexed to assess the methylation GHSR/SST/ZIC1, levels of three genes (1: 2: CDO1/MAL/PRDM14, 3: 144 C2CD4D/GALR1/NRN1) and a reference gene (ACTB, gene-ID: 60) within the same 145 146 reaction. Methylation analysis of CDO1, GALR1, GHSR, MAL, SST, PRDM14, and ZIC1 was performed as described previously^{10, 18, 19} with a shortened amplicon size of 147 ACTB, MAL and ZIC1 to facilitate methylation detection in fragmented urinary DNA. 148 Assays targeting C2CD4D and NRN1 were designed based on gene loci discovered 149 and validated by others.^{17, 21} Primer and probe information is provided in Supplemental 150 151 Table 1. Reaction conditions, instrument identifications, and thermocycling parameters are described in the Supplemental Methods. Double-stranded gBlocks[™] Gene 152 153 Fragments (Integrated DNA Technologies) containing the target amplicons and H₂O 154 were taken along in each run as positive and negative control, respectively. Sample quality and sufficient input was ensured by excluding samples with a ACTB 155 quantification cycle (Cq) \ge 32. Methylation levels were calculated relative to ACTB 156 157 levels by the comparative Cq method: 2 ^ -(Cq marker – Cq ACTB) x 100.²⁶

All qMSP assays were designed, multiplexed and optimized according to parameters 158 159 described earlier.²⁷ Target specificity was validated *in silico* (BLAST). Correct amplicon size was verified by agarose gel electrophoresis. Analytical validation was performed 160 using a dilution series of bisulfite treated methylated DNA from the SiHa cell line (100, 161 50, 10, 5, 1, 0.5%) within the range of 20 to 0.1 ng (Supplemental Table 2). The 162 discriminatory power of each assay was verified by comparing methylation marker 163 164 levels in tissue samples of ovarian cancer patients with those measured in normal fallopian tube tissue. 165

166 Shallow whole-genome sequencing

Urine cell-free DNA (cfDNA) extracted from urine supernatant samples of ovarian 167 cancer patients was further characterized by shallow whole-genome sequencing (~1x 168 169 coverage). The cfDNA was guantified and analyzed using a Cell-free DNA ScreenTape assay of the Agilent 4200 TapeStation System (Agilent) for quality control before 170 sequencing. Sequencing libraries of the first pilot series of urine supernatant DNA were 171 prepared using the ThruPLEX Plasma-seq Kit (Takara Bio, Mountain View, CA, USA) 172 for whole-genome sequencing according to manufacturers' instructions. The remaining 173 174 samples were prepared using the NEBNext® Enzymatic Methyl-seq (EM-seq) Kit (NEB, Ipswich, MA, USA). EM-seq was performed according to manufacturers' 175 176 guidelines for standard insert libraries with 14 PCR cycles. Libraries were quantified 177 and quality checked using the D1000 ScreenTape Analysis Assay (Agilent) before pooling. Paired-end 150 base pair (bp) libraries were pooled in equimolar amounts and 178 sequenced on a NovaSeq6000 (Illumina) (GenomeScan, Leiden). The processing of 179 180 sequencing data and subsequent analysis of SCNA and cfDNA fragmentation patterns are provided in the Supplemental Methods. Shallow whole-genome sequencing of 181

paired FFPE primary tumor tissue was performed to verify copy number profile
 concordance and is also described in the Supplemental Methods.

184 Statistical analysis

Methylation levels were expressed as ^{2log-}transformed Cq ratios and presented in violin 185 plots. Tissue methylation levels were compared between two groups using the non-186 parametric Mann-Whitney U test. Methylation levels of each gene in the remaining 187 sample types were compared between healthy controls and patients diagnosed with a 188 benign or malignant ovarian mass using the Kruskal-Wallis test. In case of a significant 189 190 Kruskal-Wallis test (p<0.05), this was followed by post-hoc testing of 1) healthy controls versus malignant ovarian masses, and 2) benign versus malignant ovarian masses 191 using the Mann-Whitney U test with Bonferroni correction. 192

The correlation between methylation levels of each DNA methylation marker between paired samples of patients diagnosed with ovarian cancer was assessed using Spearman's rank correlation. Correlation coefficient *r* was defined as very weak (r=0.00-0.19), weak (r=0.20-0.39), moderate (r=0.40-0.59), strong (r=0.60-0.79), or very strong (r=0.80-1.00) and displayed in correlation matrices.

Fragment size profiles were visualized by density plots and analyzed by comparing cfDNA reads of healthy controls and ovarian cancer patients with low (<5%) and high $(\geq 5\%)$ tumor fractions.

Data was collected using Castor EDC and analyzed using R (version 4.0.3 with packages: cowplot, corrplot, dplyr, ggplot, ggpubr, and rstatix). *P*-values are two-sided and considered statistically significant when p<0.05.

204

205 **RESULTS**

206 Study population

A total of 428 samples of 164 participants were analyzed within this study. Samples 207 208 were prospectively collected from 54 patients undergoing pelvic surgery at a tertiary oncology center because of a highly suspicious ovarian mass. Twenty-nine women 209 were diagnosed with ovarian cancer and 25 with a benign ovarian mass. For 210 comparison, 110 unpaired samples of healthy age-matched controls were collected. 211 Sample types included clinician-taken cervical scrapes (control n=40, benign n=22, 212 213 malignant n=24), cervicovaginal self-samples (control n=40, benign n=24, malignant n=28), full void urine (control n=30, benign n=25, malignant n=28), urine supernatant 214 (control n=29, benign n=25, malignant n=29), and urine sediment (control n=30, benign 215 216 n=25, malignant n=29). Clinical characteristics of study participants are summarized in Table 1. 217

	n	%	Age: median (IQR)	
Ovarian cancer:	29		59 (56 - 67)	
Histology				
Serous carcinoma	22	75.9%		
Low-grade	4			
High-grade	18			
Clear cell carcinoma, high-grade*	3	10.3%		
Carcinosarcoma, high-grade	2	6.9%		
Endometrioid carcinoma, low-grade	1	3.4%		
Mucinous carcinoma, low-grade	1	3.4%		
Stage (FIGO 2014)				
IIB	5	17.2%		
IIC	1	3.4%		
IIIA	5	17.2%		
IIIB	4	13.8%		
IIIC	12	41.4%		
IV	2	6.9%		
<u>Benign ovarian mass:</u>	25		62 (54 - 69)	
Histology				
Serous cystadeno(fibro)ma	8	32.0%		
Mucinous cystadenoma	6	24.0%		
Fibroma	4	16.0%		
Endometriosis cyst	4	16.0%		
Mature teratoma	3	12.0%		
Healthy controls:	110			
Sample type				
Urine	30		60 (53 - 74)	
Cervicovaginal self-sample	40		60 (60 - 60)	
Clinician-taken cervical scrape	40		60 (60 - 60)	

Table 1: Clinical characteristics of study participants.

*Including one mixed clear cell and low-grade endometrioid carcinoma.

219

DNA methylation levels are elevated in cervical scrapes and urine samples of 220

women with ovarian masses 221

The discriminatory power of qMSP assays was verified in tissue, in which all markers 222

showed clear significant differences when comparing methylation levels in normal 223

fallopian tube (n=22) with HGSOC (n=35) tissues (p<0.0001; Supplemental Figure 1, 224

Mann-Whitney U). 225

The feasibility of ovarian cancer detection in urine by methylation analysis was 226 227 evaluated by testing nine methylation markers in full void (*i.e.*, unfractionated) urine, urine supernatant, and urine sediment of healthy controls and patients diagnosed with 228 229 a benign or malignant ovarian mass (Figure 1, Supplemental Figure 2-4). When comparing healthy controls with ovarian cancer patients, three markers showed a 230 significant discrimination in full void urine (C2CD4D, p=0.008; CDO1, p=0.022; MAL. 231 p=0.008, Mann-Whitney U), one in urine supernatant (MAL, p=0.001) and one in urine 232 sediment (GHSR, p=0.018, Mann-Whitney U). Benign and malignant masses revealed 233 comparably high methylation levels for most methylation markers, except for GHSR. 234 235 GHSR showed significantly elevated methylation levels in the urine sediment of ovarian cancer patients (p=0.024, Mann-Whitney U; Figure 1, Supplemental Figure 4). 236

Similarly, the feasibility of ovarian cancer detection in cervicovaginal self-samples and 237 clinician-taken cervical scrapes by methylation analysis was assessed by testing the 238 same methylation markers. While methylation levels of two markers were significantly 239 increased in clinician-taken cervical scrapes of ovarian cancer patients as compared 240 to controls (C2CD4D, p=0.001; CDO1, p=0.004, Mann-Whitney U), benign and 241 malignant ovarian masses could not be distinguished using these markers (Figure 1, 242 Supplemental Figure 5). None of the markers were significantly elevated in 243 cervicovaginal self-samples when comparing these groups (Figure 1, Supplemental 244 245 Figure 6).

Numbers were insufficient to compare methylation levels between different histologicalsubtypes and stages.



248

249 Figure 1: Methylation levels of most discriminating markers C2CD4D, CDO1, GHSR, and MAL in full 250 void (unfractionated) urine, urine supernatant, urine sediment, cervicovaginal self-samples, and 251 clinician-taken cervical scrapes of healthy controls and patients diagnosed with a benign or malignant 252 ovarian mass. Methylation levels are expressed by 2log-transformed Cq ratios and bold circles represent 253 medians.

DNA methylation levels are correlated between paired cervical scrapes and urine 255

256 samples

DNA methylation levels of genes significantly discriminating between healthy and 257 malignant in cervical scrapes and urine (i.e., C2CD4D, CDO1, GHSR, MAL) were 258 compared between paired samples to assess their correlation (Supplemental Figure 259 7). Paired cervical scrapes and urine were available for 23 ovarian cancer patients. 260 Individual markers in full void urine correlated moderately to strongly with urine 261 supernatant (r = 0.52-0.61) and urine sediment (r = 0.67-0.76). The full void urine 262 showed the best correlation with cervical scrapes (r = 0.42-0.59), while a weak 263 correlation was observed between the urine supernatant and cervical scrapes (r =264 0.33-0.45). 265

Copy number aberrations are detectable in urine cell-free DNA 266

267 The presence of ovarian cancer-derived DNA in the urine was verified by analyzing a subset of 25 urine supernatant samples of ovarian cancer patients (n=23) and healthy 268 controls (n=2) by shallow whole-genome sequencing. Sequencing yielded a sufficient 269 read count for all samples (median mapped paired read count of 55,133,492). Shallow 270 whole-genome sequencing coverage and quality statistics per urine sample are 271 272 provided in Supplemental Table 3. Aberrant genome-wide copy number profiles were found in 4 out of 23 sequenced urine supernatant samples of ovarian cancer patients 273 (Figure 2, Supplemental Figure 8). Copy number profile concordance between urine 274 275 and the primary tumor tissue was verified for these cases (Supplementary Figure 8).





276

The patient with the highest tumor fraction also showed the highest methylation levels of *MAL* in the urine supernatant (Supplemental Figure 9). Additionally, fragment size distributions were analyzed by comparing cfDNA reads of healthy controls and ovarian cancer patients with low and high tumor fractions. Cancer samples with a high tumor fraction (n=4) revealed a shorter modal fragment size of 80 bp as compared to 111 bp in cancer samples with a low tumor fraction (n=19) and controls (n=2; Supplemental Figure 10).

288 **DISCUSSION**

Both elevated methylation levels of a subset of markers and SCNA were detected in home-collected urine samples of ovarian cancer patients by targeted qMSP assays and shallow whole-genome sequencing, respectively. Urine is truly non-invasive and unlocks at home collection of liquid biopsy to reduce in-person visits. Yet, an important finding was that methylation levels in benign cases were similarly high, presenting a challenge for the development of clinically useful tests.

While we tested for methylation markers described and also by us verified to be 295 associated with ovarian cancer, it was found that when tested in our patient-friendly 296 sample types most of these did not distinguish benign from malignant ovarian masses. 297 Only GHSR demonstrated slightly increased methylation levels in the urine sediment. 298 Benign ovarian masses included in this study were highly suspicious for malignancy 299 according to current triage methods (>40% risk of malignancy using the IOTA adnex 300 model) as samples were collected in a tertiary oncology unit. Half of the included 301 patients in our cohort were ultimately diagnosed with a benign ovarian mass, 302 underlining that current triage for referral to tertiary oncology care is suboptimal. The 303 majority of previous studies only included benign controls for methylation marker 304 discovery in tissue but not during marker validation in plasma, as recently reviewed by 305 Terp *et al.*¹⁵, or benign controls were not age-matched to cancers.²¹ Similarly, studies 306 on ovarian cancer detection in cervical scrapes did not include benign controls.^{16, 17} 307 The inclusion of age-matched patients diagnosed with benign and malignant ovarian 308 masses is essential to accurately assess the clinical value of DNA methylation testing 309 310 for ovarian cancer detection.

The presence of ovarian cancer-derived DNA in the urine is currently underexplored. So far, only Valle *et al.* reported on the detection of somatic mutation profiles and

HIST1H2BB/MAGI2 promoter methylation in a small paired series of ascites, blood,
tissue, urine, and vaginal swabs of HGSOC patients.²⁸ Their data on two patients
revealed that methylation levels in urinary cfDNA correlated stronger with tissue than
with blood, indicating the potential of urine-based ovarian cancer detection.
Unfortunately, the diagnostic potential of ovarian cancer detection in urine could not
be determined in the study of Valle *et al.* as no control samples were included.

In our study, different urine fractions were systematically compared to explore whether 319 320 a preferred urine sample type for ovarian cancer detection exists. Full void urine most likely contains both genomic and cfDNA, whereas the urine sediment is enriched for 321 genomic DNA and the urine supernatant for transrenally excreted cfDNA.²⁹ This 322 assumption is confirmed by the strong correlation for CDO1 between cervical scrapes 323 and urine sediment, while cervical scrapes and urine supernatant correlated weakly to 324 moderately. Most methylation markers significantly differentiated between healthy 325 controls and ovarian cancer patients in the full void urine (3/12), followed by urine 326 supernatant (1/12), and the urine sediment (1/12). These outcomes suggest that 327 tumor-derived methylation signals can originate from genomic DNA as well as 328 transrenally excreted cfDNA. Yet, larger samples sizes are needed to determine 329 whether a preferred urine sample type for methylation analysis exists. 330

In the present study, genes with elevated methylation levels in HGSOC tissue, were not always measurable in urine. Our qMSP assays were designed to facilitate the detection of methylation in small DNA fragments present in the urine as shown in our previous studies.^{8, 10, 12} Yet, the current assays may not reach the limit of detection needed for the low tumor-derived methylation signals. Nucleic acids that are released from the bladder epithelium may further dilute the ovarian cancer signal in urine. Another explanation for the absence of tumor-derived methylation signals of some

genes in the urine could be linked to the origin of urinary cfDNA. Urine cfDNA is 338 339 described to be even shorter as compared to plasma cfDNA (modal size of 82 vs. 167 basepairs) ³⁰. Differences in fragmentation patterns between plasma and urine are 340 likely caused by Dnase1 cleavage activity in the urine and high concentrations of urea 341 and salt that affect histone-DNA binding ³¹. Histone-bound DNA is more protected 342 against degradation as compared to DNA that is not histone-bound ³². Hypothetically, 343 hypermethylated regions of interest that are not histone-bound could be further 344 degraded and become unmeasurable. We partly accounted for this by including 345 methylation markers with proven diagnostic value in plasma in our selection (*i.e.*, 346 C2CD4D^{21, 22}, CDO1²²), which both appeared suitable for ovarian cancer detection in 347 urine. 348

Clear SCNA profiles harboring common chromosomal gains (e.g., 1q, 3q, 7q, 8q) and 349 losses (e.g., 17p, 19q, 22q) could be obtained from four urine supernatant samples of 350 ovarian cancer patients, verifying the presence of tumor-derived DNA in the urine.³³ 351 Furthermore, a focal amplification at chromosome 19 was identified in the urine of one 352 patient with stage IIIA serous carcinoma, which is a clinically relevant alteration that 353 has previously been described in a subgroup of serous ovarian cancers.³⁴ Aneuploidy 354 was detected previously in cervical scrape samples of ovarian cancer patients using 355 the PapSEEK test ¹⁶. We also observed shorter fragment sizes in urine supernatant 356 samples with a high tumor fraction, which is another indication for the presence of 357 tumor-derived DNA in the urine, as shown previously in urine samples of glioma 358 patients ³⁰. 359

Given the feasibility of ovarian cancer detection in cervical scrapes by DNA methylation
 analysis^{14, 17}, similar findings were expected for self-collected cervicovaginal samples.
 While *C2CD4D* and *CDO1* distinguished healthy versus malignant in cervical scrapes,

none of the markers showed elevated methylation levels in cervicovaginal self-363 364 samples. Our findings are in line with those of van Bommel et al. who reported that mutation analysis in cervicovaginal self-samples of ovarian cancer patients was not 365 feasible.³⁵ None of the pathogenic mutations found in surgical specimens could be 366 detected in cervicovaginal self-samples. Ovarian cancer signals might be more diluted 367 in cytological specimens collected from areas further away from the ovaries. This was 368 369 also observed for the PapSEEK test, which detected 45% of ovarian cancers when using intrauterine sampling (Tao brush) as compared to 17% when using endocervical 370 sampling (Pap brush).¹⁶ 371

Nevertheless, considering our relatively small sample size, we do not exclude the use 372 of cervicovaginal self-samples for ovarian cancer detection yet. The optimization of 373 pre-analytical factors, such as increased input of original sample or improved DNA 374 isolation methods, could enhance the ovarian cancer signal in vaginal samples. 375 Alternatively, a non-tumor DNA driven approach could be useful for ovarian cancer 376 detection in cervicovaginal self-samples, as recently described by Barrett et al.³⁶ Their 377 signature consisted of epigenetic differences in cervical cells and allowed ovarian 378 cancer detection in cervical scrapes with an area under the receiver operating 379 characteristic curve value of 0.76. Larger cohort studies, such as the Screenwide study 380 ³⁷, will provide further insight into the use of cervicovaginal self-samples for ovarian 381 cancer detection. 382

Strengths of this study include the collection of a unique paired sample series of both patients diagnosed with a benign ovarian mass and with a malignant ovarian tumor, covering most histological subtypes. Moreover, urine and cervicovaginal self-samples were collected from home to assess the feasibility and potential of home-based sampling for ovarian cancer. The successful sequencing of urine cfDNA of ovarian

cancer patients provides opportunities for future (epi)genome profiling using short- or 388 389 long-read sequencing technologies. Although we have demonstrated the potential diagnostic value of urine for ovarian cancer, this study is limited by still relatively low 390 sample numbers and the lack of early-stage cancers (\leq FIGO stage 2A). Given the 391 heterogeneous nature of benign and malignant ovarian masses, larger sample series 392 are needed to conclude on the clinical applicability of home-collected cervicovaginal 393 394 self-samples and urine for ovarian cancer detection. Furthermore, direct comparisons with paired plasma samples using DNA-based and other molecular biomarkers (e.g., 395 HE4) would be informative for future studies. 396

397 This study supports limited existing data on ovarian cancer detection in cervical scrapes by DNA methylation analysis. Moreover, it provides first proof of concept that 398 urine yields increased methylation levels of ovarian cancer-associated genes and 399 contains ovarian cancer-derived DNA as demonstrated by SCNA analysis. Our 400 findings support continued research into urine biomarkers for ovarian cancer detection 401 and highlight the importance of including benign ovarian masses in future studies. 402 Molecular biomarker testing in patient-friendly samples could facilitate earlier ovarian 403 cancer detection and triage women presenting with an ovarian mass to manage 404 specialist referral. Yet, further studies investigating alternative urine (methylation) 405 biomarkers are warranted to develop a clinically useful test. 406

407 Glossary

- 408 cfDNA: cell-free DNA
- 409 Cq: quantification cycle
- 410 FFPE: formalin-fixed paraffin-embedded
- 411 HGSOC: high grade serous ovarian cancer
- 412 hrHPV: high-risk human papillomavirus
- 413 qMSP: quantitative methylation-specific PCR
- 414 SCNA: somatic copy number aberrations

415 Acknowledgements

The authors thank Dr. Poell, Dr. Kasius, and Dr. Mom for the useful discussions and support during funding acquisition. The authors also thank Dr. Y. Kim, J.M.P Egthuijsen, N. Hogervorst, and N. Evander for technical assistance and A. Koch for help during sample collection.

420 Author contributions

BW: Funding acquisition, resources, data curation, formal analysis, investigation, 421 visualization, methodology, writing-original draft. MS: Resources, data curation, 422 writing-review and editing. MB: Conceptualization, supervision, funding acquisition, 423 validation, writing-review and editing, project administration. YB: Investigation, data 424 curation, methodology, writing-review and editing. RH: Conceptualization, resources, 425 writing-review and editing. CL: Resources, writing-review and editing. FD: Resources, 426 writing-review and editing. YP: Investigation, writing-review and editing. FM: 427 Resources, formal analysis, visualization, methodology, writing-review and editing. 428 NM: Resources, formal analysis, visualization, methodology, writing-review and 429 editing. NT: Conceptualization, supervision, funding acquisition, resources, validation, 430 writing-review and editing, project administration. RS: Conceptualization, supervision, 431 432 funding acquisition, validation, writing-original draft, project administration.

433 Funding information

This research was funded by the CCA Foundation and Maarten van der Weijden Foundation, who provided financial support for the conduct of the research and had no role in conducting the research and preparation of the manuscript. RvdH was funded by the Weijerhorst Foundation. NM and FM were funded by the Dutch Cancer Society (grant number KWF: 12822).

439 **Conflict of interest statement**

RS has a minority share in Self-screen B.V., a spin-off company of Amsterdam UMC, location VUmc. Self-screen B.V. holds patents and products related to the work. RS and FM are co-inventors on multiple patents related to methylation markers and cfDNA analysis, respectively. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

447 **Ethics statement**

All patients participating in the SOLUTION1 study were 18 years or older and signed 448 informed consent before sample collection. Ethical approval was obtained by the 449 Medical Ethical Committee of the VU University Medical Center for the use of samples 450 collected within the SOLUTION1 study (METc: 2016.213, Trial registration ID: 451 452 NL56664.029.16), samples stored in the URIC biobank (TcB 2018.657), and samples archived in the biobank containing leftover material of the Dutch national cervical 453 cancer screening program (TcB 2020.245). The Code of Conduct for Responsible Use 454 of Left-over Material of the Dutch Federation of Biomedical Scientific Societies was 455 adhered for the use of tissue specimen. 456

457 Data and code availability

The sequencing dataset generated and analyzed during the current study is available in the European Genome-Phenome Archive repository, under accession number EGAD00001010848. The DNA methylation dataset generated and analyzed during this study is available from the corresponding author on reasonable request.

perpetuity. All rights reserved. No reuse allowed without permission.

462 **REFERENCES**

463 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers 464 465 in 185 Countries. CA: A Cancer Journal for Clinicians 2021;71:209-49. 466 2. Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian 467 cancer: a systematic review. BJOG: An International Journal of Obstetrics & Gynaecology 468 2005:112:857-65. 3. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer 469 Biology and Medicine 2017;14:9-32. 470 471 4. Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, 472 Massingham SK, Raikou M, Kalsi JK, Woolas R, et al. Ovarian cancer population screening and 473 mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening 474 (UKCTOCS): a randomised controlled trial. Lancet 2021;397:2182-93. 475 5. Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, Gohagan J, Berg CD, Prorok 476 PC. Extended mortality results for ovarian cancer screening in the PLCO trial with median 477 15  years follow-up. Gynecologic Oncology 2016;143:270-75. 478 6. Ibrahim J, Peeters M, Van Camp G, Op de Beeck K. Methylation biomarkers for early 479 cancer detection and diagnosis: Current and future perspectives. European Journal of Cancer 480 2023;178:91-113. 481 7. Barrett JE, Sundström K, Jones A, Evans I, Wang J, Herzog C, Dillner J, Widschwendter M. 482 The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and 483 invasive cervical cancer. Genome Medicine 2022;14:116. 484 8. van den Helder R, Steenbergen RDM, van Splunter AP, Mom CH, Tjiong MY, Martin I, 485 Rosier-van Dunné FMF, van der Avoort IAM, Bleeker MCG, van Trommel NE. HPV and DNA 486 Methylation Testing in Urine for Cervical Intraepithelial Neoplasia and Cervical Cancer Detection. 487 Clinical Cancer Research 2022:28:2061-68. 488 9. Herzog C, Marín F, Jones A, Evans I, Reisel D, Redl E, Schreiberhuber L, Pavtubi S, 489 Pelegrina B, Carmona Á, Peremiquel-Trillas P, Frias-Gomez J, et al. A Simple Cervicovaginal 490 Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: 491 Validation in Several Cohort and Case/Control Sets. Journal of Clinical Oncology 2022;40:3828-38. 492 10. Wever BMM, van den Helder R, van Splunter AP, van Gent M, Kasius JC, Trum JW, Verhoeve HR, van Baal WM, Hulbert A, Verhoef L, Heideman DAM, Lissenberg-Witte BI, et al. DNA 493 494 methylation testing for endometrial cancer detection in urine, cervicovaginal self-samples, and cervical 495 scrapes. Int J Cancer 2023. 11. Bach S, Paulis I, Sluiter NR, Tibbesma M, Martin I, van de Wiel MA, Tuynman JB, Bahce I, 496 497 Kazemier G, Steenbergen RDM. Detection of colorectal cancer in urine using DNA methylation analysis. Scientific Reports 2021;11:2363. 498 499 12. Wever BMM, Bach S, Tibbesma M, ter Braak TJ, Wajon D, Dickhoff C, Lissenberg-Witte 500 BI, Hulbert A, Kazemier G, Bahce I, Steenbergen RDM. Detection of non-metastatic non-small-cell 501 lung cancer in urine by methylation-specific PCR analysis: A feasibility study. Lung Cancer 502 2022;170:156-64. 13. Liu B, Ricarte Filho J, Mallisetty A, Villani C, Kottorou A, Rodgers K, Chen C, Ito T, Holmes 503 504 K, Gastala N, Valyi-Nagy K, David O, et al. Detection of Promoter DNA Methylation in Urine and 505 Plasma Aids the Detection of Non-Small Cell Lung Cancer. Clin Cancer Res 2020;26:4339-48. 506 14. Chang CC, Wang HC, Liao YP, Chen YC, Weng YC, Yu MH, Lai HC. The feasibility of 507 detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings. J 508 Gynecol Oncol 2018;29:e17. 509 15. Terp SK, Stoico MP, Dybkær K, Pedersen IS. Early diagnosis of ovarian cancer based on 510 methylation profiles in peripheral blood cell-free DNA: a systematic review. Clinical Epigenetics 511 2023;15:24. 16. Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, Sundfelt K, Kjær SK, Hruban RH, 512 513 Shih IM, Wang TL, Kurman RJ, et al. Evaluation of liquid from the Papanicolaou test and other liquid 514 biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med 2018;10. 515 17. Wu T-I, Huang R-L, Su P-H, Mao S-P, Wu C-H, Lai H-C. Ovarian cancer detection by DNA 516 methylation in cervical scrapings. Clinical Epigenetics 2019;11:166. 517 18. Snoek BC, Splunter APV, Bleeker MCG, Ruiten MCV, Heideman DAM, Rurup WF, Verlaat 518 W, Schotman H, Gent MV, Trommel NEV, Steenbergen RDM. Cervical cancer detection by DNA 519 methylation analysis in urine. Sci Rep 2019;9:3088.

perpetuity. All rights reserved. No reuse allowed without permission.

520 19. van den Helder R, Wever BMM, van Trommel NE, van Splunter AP, Mom CH, Kasius JC, 521 Bleeker MCG, Steenbergen RDM. Non-invasive detection of endometrial cancer by DNA methylation 522 analysis in urine. Clinical Epigenetics 2020;12:165. 523 20. De Strooper LM, van Zummeren M, Steenbergen RD, Bleeker MC, Hesselink AT, Wisman 524 GB, Snijders PJ, Heideman DA, Meijer CJ. CADM1, MAL and miR124-2 methylation analysis in 525 cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol 2014;67:1067-71. 526 21. Widschwendter M, Zikan M, Wahl B, Lempiäinen H, Paprotka T, Evans I, Jones A, Ghazali S, Reisel D, Eichner J, Rujan T, Yang Z, et al. The potential of circulating tumor DNA methylation 527 528 analysis for the early detection and management of ovarian cancer. Genome Medicine 2017;9:116. 529 22. Marinelli LM, Kisiel JB, Slettedahl SW, Mahoney DW, Lemens MA, Shridhar V, Taylor WR, 530 Staub JK, Cao X, Foote PH, Burger KN, Berger CK, et al. Methylated DNA markers for plasma 531 detection of ovarian cancer: Discovery, validation, and clinical feasibility. Gynecol Oncol 532 2022;165:568-76. 533 23. Meys EMJ, Jeelof LS, Ramaekers BLT, Dirksen CD, Kooreman LFS, Slangen BFM, 534 Kruitwagen RFPM, Van Gorp T. Economic evaluation of an expert examiner and different ultrasound 535 models in the diagnosis of ovarian cancer. European Journal of Cancer 2018;100:55-64. 536 24. Van Calster B, Valentin L, Froyman W, Landolfo C, Ceusters J, Testa AC, Wynants L, 537 Sladkevicius P, Van Holsbeke C, Domali E, Fruscio R, Epstein E, et al. Validation of models to 538 diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study. 539 BMJ 2020;370:m2614. 25. van den Helder R, van Trommel NE, van Splunter AP, Lissenberg-Witte BI, Bleeker MCG, 540 541 Steenbergen RDM. Methylation analysis in urine fractions for optimal CIN3 and cervical cancer 542 detection. Papillomavirus Res 2020;9:100193. 543 26. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. 544 Nature Protocols 2008;3:1101-08. 545 27. Snellenberg S, Strooper LMAD, Hesselink AT, Meijer CJLM, Snijders PJF, Heideman 546 DAM, Steenbergen RDM. Development of a multiplex methylation-specific PCR as candidate triage 547 test for women with an HPV-positive cervical scrape. BMC Cancer 2012;12:551. 548 28. Valle BL, Rodriguez-Torres S, Kuhn E, Díaz-Montes T, Parrilla-Castellar E, Lawson FP, Folawiyo O, Ili-Gangas C, Brebi-Mieville P, Eshleman JR, Herman J, Shih I-M, et al. HIST1H2BB and 549 550 MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and 551 Prognosis of High-grade Serous Ovarian Cancer. Cancer Prevention Research 2020;13:783-94. 552 29. Hentschel AE, van den Helder R, van Trommel NE, van Splunter AP, van Boerdonk RAA, van Gent M, Nieuwenhuijzen JA, Steenbergen RDM. The Origin of Tumor DNA in Urine of Urogenital 553 554 Cancer Patients: Local Shedding and Transrenal Excretion. Cancers (Basel) 2021;13. 555 30. Mouliere F, Smith CG, Heider K, Su J, van der Pol Y, Thompson M, Morris J, Wan JCM, 556 Chandrananda D, Hadfield J, Grzelak M, Hudecova I, et al. Fragmentation patterns and personalized 557 sequencing of cell-free DNA in urine and plasma of glioma patients. EMBO Mol Med 2021;13:e12881. 558 31. Chen M, Chan RWY, Cheung PPH, Ni M, Wong DKL, Zhou Z, Ma ML, Huang L, Xu X, Lee 559 WS, Wang G, Lui KO, et al. Fragmentomics of urinary cell-free DNA in nuclease knockout mouse 560 models. PLoS Genet 2022;18:e1010262. 32. Han DSC, Ni M, Chan RWY, Chan VWH, Lui KO, Chiu RWK, Lo YMD. The Biology of 561 562 Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. Am J Hum Genet 563 2020;106:202-14. 33. Micci F, Haugom L, Abeler VM, Davidson B, Tropé CG, Heim S. Genomic profile of 564 565 ovarian carcinomas. BMC Cancer 2014;14:315. 566 34. Sung CO, Song I-H, Sohn I. A distinctive ovarian cancer molecular subgroup characterized 567 by poor prognosis and somatic focal copy number amplifications at chromosome 19. Gynecologic 568 oncology 2014;132:343-50. 569 35. van Bommel MHD, Pijnenborg JMA, van der Putten LJM, Bulten J, Snijders MPLM, 570 Küsters-Vandevelde HVN, Sweegers S, Vos MC, Ligtenberg MJL, Eijkelenboom A, de Hullu JA, 571 Reijnen C. Diagnostic accuracy of mutational analysis along the Müllerian tract to detect ovarian 572 cancer. International Journal of Gynecologic Cancer 2022;32:1568-75. 573 36. Barrett JE, Jones A, Evans I, Reisel D, Herzog C, Chindera K, Kristiansen M, Leavy OC, 574 Manchanda R, Bjørge L, Zikan M, Cibula D, et al. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nat Commun 2022;13:448. 575 576 37. Peremiguel-Trillas P, Paytubi S, Pelegrina B, Frias-Gomez J, Carmona Á, Martínez JM, de 577 Francisco J, Benavente Y, Barahona M, Briansó F, Canet-Hermida J, Caño V, et al. An Integrated 578 Approach for the Early Detection of Endometrial and Ovarian Cancers (Screenwide Study): Rationale, 579 Study Design and Pilot Study. Journal of Personalized Medicine 2022;12:1074.